News

B.C. funds new cancer treatment test

By The Canadian Press

VANCOUVER - B.C. has become the latest province to fund a test that can help determine whether patients with a certain type of early stage breast cancer could benefit from chemotherapy.

California-based Genomic Health says the BC Cancer Agency has agreed to fund the company's Oncotype DX test.

The test, which costs US$4,300, examines genes within breast cancer tumours to predict which patients would benefit from chemotherapy.

Conversely, the test is also used to predict which patients would see little or no benefit from chemotherapy.

The funding applies to patients that meet a list of criteria, including that they have early stage, node-negative, estrogen receptor-positive invasive breast cancer.

The test is already funded by provincial governments in Alberta, Ontario, Quebec, Saskatchewan, and Newfoundland and Labrador.

We encourage an open exchange of ideas on this story's topic, but we ask you to follow our guidelines for respecting community standards. Personal attacks, inappropriate language, and off-topic comments may be removed, and comment privileges revoked, per our Terms of Use. Please see our FAQ if you have questions or concerns about using Facebook to comment.

You might like ...

Province okays transit tax referendum question, with some tweaks
 
New autism centre to open in 2016
 
Surrey murder victim identifed as Jaylen Sandhu, 17
Missing New West woman surfaces in Quebec
 
Police show solidarity for officer charged with murder
 
Second Langley farm hit by avian flu
Surrey boy, 3, struck and abandoned
 
Surrey RCMP officer to stand trial on multiple gun charges
 
Federal court denies Burnaby appeal

Community Events, December 2014

Add an Event


Read the latest eEdition

Browse the print edition page by page, including stories and ads.

Dec 19 edition online now. Browse the archives.